The previous study on NAFLD and NASH patients reported increased VAP-1 concentration in fibrosis stage F ≥ 2 in comparison to F0/F1, whereas our study shows a stronger correlation with progressive fibrosis. The gene discussed is AOC3; the disease is metabolic dysfunction-associated steatohepatitis.